Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 7, 2017, Pages 881-888

  Martinez, Fernando J ^a,b   Vestboy, Jørgen ^c   Anderson, Julie A ^d   Brook, Robert D ^b   Celli, Bartolome R ^e   Cowans, Nicholas J ^f   Crim, Courtney ^g   Dransfield, Mark ^h   Kilbride, Sally ^d   Yates, Julie ^g   Newby, David E ⁱ   Niewoehner, Dennis ^j   Calverley, Peter M A ^k  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d Ortho Clinical Diagnostics   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f Veramed Ltd ^*  (United Kingdom)

^g Research and Development Research   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF MINNESOTA   (United States)

^k UNIVERSITY OF LIVERPOOL   (United Kingdom)

more..

Author keywords

Cardiovascular disease; COPD; Exacerbations; Fluticasone Furoate; Vilanterol

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS VILANTEROL; PLACEBO; VILANTEROL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COMPLICATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; AIRWAY OBSTRUCTION; ANDROSTADIENES; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 85017356963     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201607-1421OC     Document Type: Article

References (35)

1. Vestbo J, Hurd SS, Agust? AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, , et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187: 347-365.
2. Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2016;11:21-30.
3. Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, Curren K, Balter MS, Bhutani M, Camp PG, , et al. Executive summary: Prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest 2015;147: 883-893.
4. Woodruff PG, Agusti A, Roche N, Singh D, Martinez FJ. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: Making progress towards personalised management. Lancet 2015;385:1789-1798.
5. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mü llerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, , et al. ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363: 1128-1138.
6. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE; SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet 2016;387:1817-1826.
7. Vestbo J, Anderson J, Brook RD, Calverley PM, Celli BR, Crim C, Haumann B, Martinez FJ, Yates J, Newby DE. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur Respir J 2013;41:1017-1022.
8. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U. S. population. Am J Respir Crit Care Med 1999;159:179-187.
9. Halpin DM. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: The value of NNT analysis. Int J Clin Pract 2005;59:1187-1194.
10. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012;39:38-45.
11. Donaldson GC, Goldring JJ, Wedzicha JA. Influence of season on exacerbation characteristics in patients with COPD. Chest 2012;141: 94-100.
12. Rabe KF, Fabbri LM, Vogelmeier C, Kö gler H, Schmidt H, Beeh KM, Glaab T. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest 2013;143:711-719.
13. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; (4):CD003794.
14. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and longacting beta(2)-agonist in one inhaler versus long-acting beta(2)-A gonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD006829.
15. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;8:CD006826.
16. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59.
17. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
18. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
19. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789.
20. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
21. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One 2012;7:e47305.
22. Wang Z, Bafadhel M, Haldar K, Spivak A, Mayhew D, Miller BE, Tal-Singer R, Johnston SL, Ramsheh MY, Barer MR, , et al. Lung microbiome dynamics in COPD exacerbations. Eur Respir J 2016;47: 1082-1092.
23. Freeman CM, Crudginton SW, Stolberg VR, McCubbrey AL, Todt JC, Brown JP, McCloskey L, Curtis JL. Glucocorticoid-augmented efferocytosis impairs host defense by alveolar macrophages of human smokers by reducing specific microRNAs [abstract]. Am J Respir Crit Care Med 2015;191:A5383.
24. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, Wedzicha JA; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest 2011;139:505-512.
25. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, , et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12:27-34.
26. Iannella H, Luna C, Waterer G. Inhaled corticosteroids and the increased risk of pneumonia: What's new? A 2015 updated review. Ther Adv Respir Dis 2016;10:235-255.
27. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, , et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.
28. Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, Barnes NC. Blood eosinophils and inhaled corticosteroid/long-acting b-2 agonist efficacy in COPD. Thorax 2016;71:118-125.
29. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
30. Huerta A, Donaldson GC, Singh R, Mackay AJ, Allinson JP, Brill SE, Kowlessar B, Torres A, Wedzicha JA. Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2015;12:997-1004.
31. MacDonald M, Beasley RW, Irving L, Bardin PG. A hypothesis to phenotype COPD exacerbations by aetiology. Respirology 2011;16: 264-268.
32. MacDonald M, Korman T, King P, Hamza K, Bardin P. Exacerbation phenotyping in chronic obstructive pulmonary disease. Respirology 2013;18:1280-1281.
33. Lopez-Campos JL, Agust? A. Heterogeneity of chronic obstructive pulmonary disease exacerbations: A two-axes classification proposal. Lancet Respir Med 2015;3:729-734.
34. Suissa S. Number needed to treat in COPD: Exacerbations versus pneumonias. Thorax 2013;68:540-543.
35. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016;374:2222-2234.